ReviewJournal of cellular and molecular medicine2008
Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool.
Review in Journal of cellular and molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- 3D Osteoimmune Stem Cell Spheroids with Osteoinduction and Immunomodulation Dual Functionality forACS biomaterials science & engineering · 2026Article
- Live monitoring uncovers divergent epigenetic remodeling during osteogenic and adipogenic differentiation of mesenchymal stem cells.Frontiers in cell and developmental biology · 2026Article
- Nano-biomaterials and advanced fabrication techniques for engineering skeletal muscle tissue constructs in regenerative medicine.Nano convergence · 2023Review
- Cellular dynamics of distinct skeletal cells and the development of osteosarcoma.Frontiers in endocrinology · 2023Review
- Skin-Derived ABCB5International journal of molecular sciences · 2022Review
- Anti-inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model.Veterinary medicine and science · 2022Article
- Polydatin Incorporated in Polycaprolactone Nanofibers Improves Osteogenic Differentiation.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Multifunctional GelMA platforms with nanomaterials for advanced tissue therapeutics.Bioactive materials · 2022Review
- DNA/Magnetic Nanoparticles Composite to Attenuate Glass Surface Nanotopography for Enhanced Mesenchymal Stem Cell Differentiation.Polymers · 2022Article
- Therapeutics effect of mesenchymal stromal cells in reactive oxygen species-induced damages.Human cell · 2022Review
- Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.Journal of clinical medicine · 2021Review
- Intracellular role of IL-6 in mesenchymal stromal cell immunosuppression and proliferation.Scientific reports · 2020Article
- Transplantation of Umbilical Cord-Derived Mesenchymal Stem Cells Overexpressing Lipocalin 2 Ameliorates Ischemia-Induced Injury and Reduces Apoptotic Death in a Rat Acute Myocardial Infarction Model.Stem cell reviews and reports · 2020Article
- Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells.Molecular therapy. Nucleic acids · 2020Article
- Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery.Molecular therapy. Methods & clinical development · 2020Review
- Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy.The Journal of pharmacology and experimental therapeutics · 2019Review
- CDKN2B upregulation prevents teratoma formation in multipotent fibromodulin-reprogrammed cells.The Journal of clinical investigation · 2019Article
- Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells Are Functionally and Genetically Different From Bone Marrow-Derived Mesenchymal Stromal Cells.Stem cells (Dayton, Ohio) · 2019Article
- Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory inHaematologica · 2019Article
- Stem cell therapy for nerve injury.World journal of stem cells · 2017Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) from adult somatic tissues may differentiate in vitro and in vivo into multiple mesodermal tissues including bone, cartilage, adipose tissue, tendon, ligament or even muscle. MSCs preferentially home to damaged tissues where they exert their therapeutic potential. A striking feature of the MSCs is their low inherent immunogenicity as they induce little, if any, proliferation of allogeneic lymphocytes and antigen-presenting cells. Instead, MSCs appear to be immunosuppressive in vitro. Their multilineage differentiation potential coupled to their immuno-privileged properties is being exploited worldwide for both autologous and allogeneic cell replacement strategies. Here, we introduce the readers to the biology of MSCs and the mechanisms underlying immune tolerance. We then outline potential cell replacement strategies and clinical applications based on the MSCs immunological properties. Ongoing clinical trials for graft-versus-host-disease, haematopoietic recovery after co-transplantation of MSCs along with haematopoietic stem cells and tissue repair are discussed. Finally, we review the emerging area based on the use of MSCs as a target cell subset for either spontaneous or induced neoplastic transformation and, for modelling non-haematological mesenchymal cancers such as sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.